Project Grant R01AI198215
Award Date 8/12/26
Completion Date 7/31/31
Dollars Obligated $782K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $772,010 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct mechanistic studies of combination adjuvants in B cell memory establishment. The research examines how three adjuvants formulated together in a vaccine—an NKT cell agonist, a TLR7 agonist, and a QB virus-like particle (VLP)—cooperate to produce high-affinity protective anti-bacterial glycan...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $695,041 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms underlying combination adjuvant-driven improvement of influenza vaccine responses. The research defines the innate immune signatures and adaptive immune responses elicited by existing and novel combination adjuvants as they relate to driving immune responses directed against influenza virus...
- The National Institute of Allergy and Infectious Diseases awarded The Leland Stanford Junior University $180,929 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model immune and microbiota development in predicting child health outcomes. The research integrates longitudinal immune and microbiota monitoring to predict beneficial immune states associated with strong responses to routine immunization in children. The project leverages existing...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $503,876 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cell-intrinsic immunomodulators as molecular adjuvants for next-generation self-amplifying RNA (saRNA) vaccines. The research addresses limitations of current mRNA-LNP vaccines by developing saRNA-mediated co-expression of vaccine antigens with cell-intrinsic immunomodulators from a single RNA...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $865,432 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to dissect the mechanisms of action of saponin combination adjuvants for vaccine development. The award funds research into saponin/monophosphoryl lipid A nanoparticles (SMNP), cage-like nanostructures that combine saponins derived from the Chilean soapbark tree with a Toll-like receptor-4 agonist. The...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $3.679 million on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop self-assembling protein nanoparticles presenting stabilized hemagglutinin, neuraminidase, and M2E antigens for universal influenza vaccine development. The research addresses the structural and immunological challenges of creating a vaccine effective against both seasonal and pandemic...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded The Leland Stanford Junior University $1,818,562 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate optimal antimalarial chemoprevention regimens combined with the R21 malaria vaccine in perennial, high-transmission settings. The research will test whether combining the R21 vaccine with either monthly...
- The National Institute of Allergy and Infectious Diseases awarded $721,365 to the University of California Irvine on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a single-dose influenza vaccine platform that extends immune response breadth against viral variants. The funded research combines nanoparticles presenting H5 hemagglutinin antigen with thermo-responsive polymer depots that release antigen slowly, extending exposure time to elicit...
- The National Institute of Allergy and Infectious Diseases awarded The Leland Stanford Junior University $809,250 on April 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance induced pluripotent stem cell (iPSC)-derived thymic epithelial cells as cell therapy for T cell immune reconstitution in vulnerable populations. The research develops regenerative thymic tissues to restore immune function in patients with thymic compromise from genetic mutations,...
- The National Institute of Allergy and Infectious Diseases awarded The Leland Stanford Junior University $1.265 million on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance a novel oral direct-acting antiviral therapeutic against influenza A virus toward clinical development. Stanford will optimize two lead small-molecule compounds targeting the amphipathic helix motif in the IAV M2 protein. The lead molecule, STF-8562, demonstrates a mechanism...